Capricorn Fund Managers Ltd Makes New $961,000 Investment in Maravai LifeSciences Holdings, Inc. $MRVI

Capricorn Fund Managers Ltd purchased a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the first quarter, Holdings Channel.com reports. The firm purchased 339,727 shares of the company’s stock, valued at approximately $961,000.

Other hedge funds have also bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Maravai LifeSciences during the fourth quarter worth $34,000. T. Rowe Price Investment Management Inc. increased its position in shares of Maravai LifeSciences by 2.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after acquiring an additional 178,445 shares during the period. Invesco Ltd. increased its position in shares of Maravai LifeSciences by 12.3% in the 4th quarter. Invesco Ltd. now owns 345,773 shares of the company’s stock valued at $1,124,000 after acquiring an additional 37,958 shares during the period. Mackenzie Financial Corp raised its stake in Maravai LifeSciences by 1.7% in the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after acquiring an additional 104,355 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Maravai LifeSciences in the 4th quarter worth $7,670,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $6.24 on Wednesday. The business’s 50-day moving average is $4.64 and its two-hundred day moving average is $3.81. The company has a market capitalization of $1.61 billion, a P/E ratio of -8.79 and a beta of 0.72. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.99 and a fifty-two week high of $6.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The business had revenue of $65.84 million during the quarter, compared to analysts’ expectations of $53.00 million. Research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on MRVI. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research note on Friday, May 8th. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Wells Fargo & Company increased their price target on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.50.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.